Seeking to Bring New Options to
Patients with Blood Cancers

Seeking to Bring New Options to Patients with Blood Cancers

ABOUT US

We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers.

PACRITINIB

CTI is evaluating pacritinib in the Phase 3 PACIFICA trial for patients with myelofibrosis and severe thrombocytopenia.

INVESTORS

For the latest corporate updates and press releases please visit the investor section of our website.

PATIENTS

We are actively recruiting individuals with myelofibrosis to participate in clinical trials.

Recent News

CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

SEATTLE, Oct. 13, 2020 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration… Read More

CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

SEATTLE, Sept. 29, 2020 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration (“FDA” or “the Agency”), the Company has reached an agreement to… Read More

CTI BioPharma Reports Second Quarter 2020 Financial Results

SEATTLE, Aug. 6, 2020 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020.. Read More

CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial

SEATTLE, June 1, 2020 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19… Read More